ICU Medical (ICUI) – Investment Analysts’ Recent Ratings Changes

ICU Medical (NASDAQ: ICUI) recently received a number of ratings updates from brokerages and research firms:

• 8/8/2026 – ICU Medical was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/7/2026 – ICU Medical had its price target raised by BTIG Research from $170.00 to $200.00. They now have a “buy” rating on the stock.
• 8/7/2026 – ICU Medical had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $200.00 price target on the stock.
• 8/7/2026 – ICU Medical had its price target raised by Piper Sandler from $163.00 to $195.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – ICU Medical had its price target raised by Needham & Company LLC from $165.00 to $187.00. They now have a “buy” rating on the stock.
• 7/28/2026 – ICU Medical was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/23/2026 – ICU Medical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 7/21/2026 – ICU Medical had its price target raised by KeyCorp from $164.00 to $182.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – ICU Medical was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/15/2026 – ICU Medical was downgraded by Sanford C. Bernstein to “market perform”.
• 6/15/2026 – ICU Medical is now covered by BTIG Research. They set a “buy” rating and a $170.00 price target on the stock.
• 6/15/2026 – ICU Medical is now covered by BTIG Research. They set a “buy” rating and a $170.00 price target on the stock.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.10% of the stock is currently owned by corporate insiders.

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.